Building on the Translational Science Benefits Model to include team science: a practical and theory-based approach to continuous quality improvement and impact evaluation for Clinical and Translational Science Award programs
- PMID: 40458088
- PMCID: PMC12127396
- DOI: 10.3389/fpubh.2025.1581205
Building on the Translational Science Benefits Model to include team science: a practical and theory-based approach to continuous quality improvement and impact evaluation for Clinical and Translational Science Award programs
Abstract
Introduction: Clinical and Translational Science Award (CTSA) programs seek to improve the quality and impact of clinical and translational science. CTSA evaluation teams implement structured, evidence-based continuous quality improvement (CQI) processes to enhance activities and outcomes, ultimately benefiting public health. The Translational Science Benefits Model (TSBM) provides a framework for assessing translational science's health and societal impact, yet additional tools are needed to integrate CQI with impact evaluation. Addressing this gap requires combining CQI methodologies with team science approaches. Building on TSBM, CQI theories (e.g., Plan-Do-Study-Act cycles), and team science principles (e.g., inclusive leadership), we propose a theory-driven, evidence-based logic model to enhance CTSA programs. Using our TL1 Regenerative Medicine Training Program (RMTP) as a case study, we demonstrate its practical application for CTSA evaluation teams.
Methods: We conducted a literature review on impact evaluation, CQI, and team science to develop a theory-based approach for CTSA evaluation teams. Using case study methodology, we analyzed RMTP data (2015-2023) through: (a) Interviews with RMTP leaders, mentors, and trainees to explore program implementation and outcomes; (b) Document analysis of program materials, meeting notes, and reports; (c) Bibliometric and policy analysis of publications, citations, and policy documents to assess impact; and (d) Surveys to capture trainees' perspectives on program quality and leadership. This mixed-methods approach provided a comprehensive assessment of RMTP's impact and demonstrated the utility of our team science-based approach to CQI and evaluation.
Results: Our sample included RMTP directors (N = 2), mentors (N = 24), and trainees (N = 38). Among trainees, 68% identified as female, and 21% were from underrepresented groups in medicine. Of 34 graduates, 31 continued in regenerative medicine research. Qualitative data highlighted CQI strategies, such as embedding evaluation into advisory meetings to enhance program functioning. Inclusive leadership fostered a climate where diverse perspectives informed improvements. Quantitative and document analysis further demonstrated how RMTP activities led to positive health and societal impacts within the TSBM framework.
Discussion: CTSA evaluation teams must integrate CQI and impact evaluation, yet few theory-based approaches exist. Our evaluation and CQI framework merges TSBM, CQI, and team science principles, providing a practical tool for guiding evaluation teams in continuous improvement while maximizing translational science impact.
Keywords: Clinical and Translational Science Award; Translational Science Benefits Model; continuous quality improvement; evaluation; logic models.
Copyright © 2025 Brimhall, Kuhfeldt, Kotton and Jones.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Navigating the road ahead: using concept mapping to assess Clinical and Translational Science Award (CTSA) program goals.Front Public Health. 2025 Mar 31;13:1562191. doi: 10.3389/fpubh.2025.1562191. eCollection 2025. Front Public Health. 2025. PMID: 40231183 Free PMC article.
-
Examining rural health equity and impact through the translational science benefits model: outcomes from the CTSA Consortium of Rural States (CORES).Front Public Health. 2025 Apr 28;13:1538494. doi: 10.3389/fpubh.2025.1538494. eCollection 2025. Front Public Health. 2025. PMID: 40356836 Free PMC article.
-
Clinical and translational science award T32/TL1 training programs: program goals and mentorship practices.J Clin Transl Sci. 2021 Dec 27;6(1):e13. doi: 10.1017/cts.2021.884. eCollection 2022. J Clin Transl Sci. 2021. PMID: 35211339 Free PMC article.
-
A scoping review of continuous quality improvement in healthcare system: conceptualization, models and tools, barriers and facilitators, and impact.BMC Health Serv Res. 2024 Apr 19;24(1):487. doi: 10.1186/s12913-024-10828-0. BMC Health Serv Res. 2024. PMID: 38641786 Free PMC article.
-
Impacts of continuous quality improvement in Aboriginal and Torres Strait islander primary health care in Australia.J Health Organ Manag. 2018 Jun 18;32(4):545-571. doi: 10.1108/JHOM-02-2018-0056. Epub 2018 Jun 15. J Health Organ Manag. 2018. PMID: 29969347 Review.
References
-
- Department of Health and Human Services . PAR-24-272: Clinical and Translational Science Award (UM1 Clinical Trial Optional). NIH. Available online at: https://grants.nih.gov/grants/guide/pa-files/PAR-24-272.html (accessed February 6, 2025).
-
- Luke DA, Sarli CC, Suiter AM, Carothers BJ, Combs TB, Allen JL, et al. . The translational science benefits model: a new framework for assessing the health and societal benefits of clinical and translational sciences. Clin Transl Sci. (2018) 11:77–84. doi: 10.1111/CTS.12495, PMID: - DOI - PMC - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous